Literature DB >> 26243875

IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions.

Laurel A Monticelli1, Lisa C Osborne1, Mario Noti2, Sara V Tran1, Dietmar M W Zaiss3, David Artis4.   

Abstract

The barrier surfaces of the skin, lung, and intestine are constantly exposed to environmental stimuli that can result in inflammation and tissue damage. Interleukin (IL)-33-dependent group 2 innate lymphoid cells (ILC2s) are enriched at barrier surfaces and have been implicated in promoting inflammation; however, the mechanisms underlying the tissue-protective roles of IL-33 or ILC2s at surfaces such as the intestine remain poorly defined. Here we demonstrate that, following activation with IL-33, expression of the growth factor amphiregulin (AREG) is a dominant functional signature of gut-associated ILC2s. In the context of a murine model of intestinal damage and inflammation, the frequency and number of AREG-expressing ILC2s increases following intestinal injury and genetic disruption of the endogenous AREG-epidermal growth factor receptor (EGFR) pathway exacerbated disease. Administration of exogenous AREG limited intestinal inflammation and decreased disease severity in both lymphocyte-sufficient and lymphocyte-deficient mice, revealing a previously unrecognized innate immune mechanism of intestinal tissue protection. Furthermore, treatment with IL-33 or transfer of ILC2s ameliorated intestinal disease severity in an AREG-dependent manner. Collectively, these data reveal a critical feedback loop in which cytokine cues from damaged epithelia activate innate immune cells to express growth factors essential for ILC-dependent restoration of epithelial barrier function and maintenance of tissue homeostasis.

Entities:  

Keywords:  inflammatory bowel disease; innate immunity; innate lymphoid cell; interleukin-33

Mesh:

Substances:

Year:  2015        PMID: 26243875      PMCID: PMC4553775          DOI: 10.1073/pnas.1509070112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: ulcerative colitis shows specific p53- and EGFR expression alterations.

Authors:  Ferenc Sipos; Béla Molnár; Tamás Zágoni; Lajos Berczi; Zsolt Tulassay
Journal:  Dis Colon Rectum       Date:  2005-04       Impact factor: 4.585

2.  Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis.

Authors:  Luca Pastorelli; Rekha R Garg; Sharon B Hoang; Luisa Spina; Benedetta Mattioli; Melania Scarpa; Claudio Fiocchi; Maurizio Vecchi; Theresa T Pizarro
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

3.  Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodium-induced colitis.

Authors:  Hirotsugu Imaeda; Akira Andoh; Tomoki Aomatsu; Kazuhiko Uchiyama; Shigeki Bamba; Tomoyuki Tsujikawa; Yuji Naito; Yoshihide Fujiyama
Journal:  Int J Mol Med       Date:  2011-06-08       Impact factor: 4.101

4.  Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism.

Authors:  Fang Yan; Hanwei Cao; Timothy L Cover; M Kay Washington; Yan Shi; LinShu Liu; Rupesh Chaturvedi; Richard M Peek; Keith T Wilson; D Brent Polk
Journal:  J Clin Invest       Date:  2011-05-23       Impact factor: 14.808

5.  Amphiregulin-dependent mucous cell metaplasia in a model of nonallergic lung injury.

Authors:  Nicholas D Manzo; W Michael Foster; Barry R Stripp
Journal:  Am J Respir Cell Mol Biol       Date:  2012-04-05       Impact factor: 6.914

6.  IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs.

Authors:  Kathleen R Bartemes; Koji Iijima; Takao Kobayashi; Gail M Kephart; Andrew N McKenzie; Hirohito Kita
Journal:  J Immunol       Date:  2011-12-23       Impact factor: 5.422

7.  Interleukin-33: a mediator of inflammation targeting hematopoietic stem and progenitor cells and their progenies.

Authors:  Hongnga Le; Wonyoung Kim; Juyang Kim; Hong R Cho; Byungsuk Kwon
Journal:  Front Immunol       Date:  2013-05-06       Impact factor: 7.561

8.  Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis.

Authors:  Loris R Lopetuso; Franco Scaldaferri; Theresa T Pizarro
Journal:  Fibrogenesis Tissue Repair       Date:  2012-10-14

Review 9.  Innate immunity modulation by the IL-33/ST2 system in intestinal mucosa.

Authors:  Marina García-Miguel; M Julieta González; Rodrigo Quera; Marcela A Hermoso
Journal:  Biomed Res Int       Date:  2012-12-04       Impact factor: 3.411

10.  A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis.

Authors:  Maryam Salimi; Jillian L Barlow; Sean P Saunders; Luzheng Xue; Danuta Gutowska-Owsiak; Xinwen Wang; Li-Chieh Huang; David Johnson; Seth T Scanlon; Andrew N J McKenzie; Padraic G Fallon; Graham S Ogg
Journal:  J Exp Med       Date:  2013-12-09       Impact factor: 14.307

View more
  200 in total

Review 1.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

2.  IL-33-Mediated Expansion of Type 2 Innate Lymphoid Cells Protects from Progressive Glomerulosclerosis.

Authors:  Jan-Hendrik Riedel; Martina Becker; Kerstin Kopp; Mathis Düster; Silke R Brix; Catherine Meyer-Schwesinger; Luis A Kluth; Ann-Christin Gnirck; Madena Attar; Sonja Krohn; Boris Fehse; Rolf A K Stahl; Ulf Panzer; Jan-Eric Turner
Journal:  J Am Soc Nephrol       Date:  2017-02-02       Impact factor: 10.121

3.  IL-33 Induces Murine Intestinal Goblet Cell Differentiation Indirectly via Innate Lymphoid Cell IL-13 Secretion.

Authors:  Amanda Waddell; Jefferson E Vallance; Amy Hummel; Theresa Alenghat; Michael J Rosen
Journal:  J Immunol       Date:  2018-12-07       Impact factor: 5.422

Review 4.  Dual oxidase: a novel therapeutic target in allergic disease.

Authors:  Albert van der Vliet; Karamatullah Danyal; David E Heppner
Journal:  Br J Pharmacol       Date:  2018-03-15       Impact factor: 8.739

5.  IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental Ileitis.

Authors:  Carlo De Salvo; Xiao-Ming Wang; Luca Pastorelli; Benedetta Mattioli; Sara Omenetti; Kristine A Buela; Saleem Chowdhry; Rekha R Garg; Wendy A Goodman; Alex Rodriguez-Palacios; Dirk E Smith; Derek W Abbott; Fabio Cominelli; Giorgos Bamias; Wei Xin; James J Lee; Maurizio Vecchi; Theresa T Pizarro
Journal:  Am J Pathol       Date:  2016-02-22       Impact factor: 4.307

Review 6.  The balance of power: innate lymphoid cells in tissue inflammation and repair.

Authors:  Jim G Castellanos; Randy S Longman
Journal:  J Clin Invest       Date:  2019-06-10       Impact factor: 14.808

7.  Immunity without innate lymphoid cells.

Authors:  Robert Weinkove; Kara Filbey; Graham Le Gros
Journal:  Nat Immunol       Date:  2016-10-19       Impact factor: 25.606

8.  ILC2: There's a New Cell in Town.

Authors:  Yuan Min Wang; Mahnoor Bakhtiar; Stephen I Alexander
Journal:  J Am Soc Nephrol       Date:  2017-05-31       Impact factor: 10.121

Review 9.  Innate Lymphoid Cell Immunometabolism.

Authors:  Timothy E O'Sullivan; Joseph C Sun
Journal:  J Mol Biol       Date:  2017-09-01       Impact factor: 5.469

10.  Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.

Authors:  Hayato Nakagawa; Nobumi Suzuki; Yoshihiro Hirata; Yohko Hikiba; Yoku Hayakawa; Hiroto Kinoshita; Sozaburo Ihara; Koji Uchino; Yuji Nishikawa; Hideaki Ijichi; Motoyuki Otsuka; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Norihiro Kokudo; Keisuke Tateishi; Kazuhiko Koike
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.